Answers are grounded in this paper and cite their sources.
This focus issue is the result of years of a growing awareness of a gap in coordination and resources for plant disease diagnostic assay development and validation.The existing and emerging plant health problems on a vast array of plant hosts mean that we are often responding to an outbreak even before there is a well-validated diagnostic test.With risk and pathway analyses, which provide intelligence about the likelihood of a serious potential problem, there is the opportunity to develop and validate diagnostic assays in a timely manner.The problems that we do not see coming tax the ability to quickly develop and validate a diagnostic assay.The development and validation of new tests or assays, and further evaluation of the performance of the test or assay under new conditions, are not coordinated within the U.S. biosecurity system.An American Phytopathological Society (APS) symposium in 2017 explored aspects of assay validation.That symposium was the first time that many of us were introduced to concepts such as fitness for purpose, assay validation research, and the vocabulary that refers to the performance metrics of a diagnostic assay.At the same APS meeting, we met with European colleagues who were beginning their VALITEST project (Trontin et al. 2021 and 2023 in this focus issue).Additionally, with the intent to harmonize the language and practice of diagnostic test validation in the United States, APS published a glossary of diagnostic assay validation terminology (Cardwell et al. 2018), followed by a Plant Health Progress article on the Principles of Diagnostic Assay Validation for Plant Pathogens (Cardwell et al. 2019).In 2020, a group of research collaborators launched a National Institute of Food and Agriculture seed grant (NIFA 2020) to gather as much information as possible about how diagnostic assays were being developed within the United States and to what degree validation research was being conducted.A desk study published by Sharma and Luster (2023) in this focus issue confirmed that there was little consensus on what metrics were needed, and few publications about diagnostic assays contained more than cursory descriptions of validation.Summaries of the outcomes of the 2020 NIFA seed grant deliberations appear in six perspective articles in this focus issue, which are summarized in the article by Cardwell et al. (2023).This PhytoFrontiers focus issue was developed to house the perspective articles derived from discussions among a large group of experts over several years during the NIFA seed grant and to create a space for other perspectives and research papers specific to plant disease diagnostic assay validation.The primary objective of the focus issue was to raise awareness about the importance of assay validation for diagnostic accuracy.Reviewers were instructed to pay attention to assay validation parameters.Authors were asked to explicitly state the purpose of the assay (fitness for purpose) and to describe which of the following validation parameters were addressed and how: analytical and diagnostic specificity, analytical and diagnostic sensitivity, repeatability, and reproducibility.Not all purposes for an assay require all parameters of validation, but, if parameters were not addressed in the manuscript, authors were encouraged to state the potential consequences of not knowing the omitted performance characteristics.The purpose is to provide the diagnostician user with what they should expect of the assay and to determine whether other confirmatory methods might be needed to assure a correct diagnosis.
No takes yet. Share an insight, caveat, or question.
Cardwell et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: